Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
06:05am, Monday, 07'th Oct 2024
BeiGene (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the U.S. Food and Drug Administration (FDA) Oncologi
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
06:00am, Thursday, 26'th Sep 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board
Phonak + Advanced Bionics sponsor new family film, Rally Caps - Worldwide release on September 10th
07:02am, Monday, 09'th Sep 2024
STÄFA, Switzerland & VALENCIA, Calif.--(BUSINESS WIRE)-- #cochlear--Phonak, a leading provider of life-changing hearing solutions, and its sister brand and partner Advanced Bionics (AB), a global lea
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
01:00am, Monday, 09'th Sep 2024
BASEL, Switzerland--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA® (tislelizumab) at the Euro
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
10:57am, Wednesday, 28'th Aug 2024
The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
10:55am, Monday, 26'th Aug 2024
BeiGene, Ltd. (BGNE) is looking like an interesting pick from a technical perspective, as the company reached a key level of support.
BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
06:00am, Monday, 26'th Aug 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FD
Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
10:55am, Monday, 12'th Aug 2024
The consensus price target hints at a 40.9% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
06:00am, Friday, 14'th Jun 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of new data from the SEQUOIA study
DUBAI, United Arab Emirates--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conc
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
06:01am, Tuesday, 04'th Jun 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the Company will participate in the Goldman Sa
7 Large-Cap Stocks That Can Jump 50% By 2025
07:07am, Wednesday, 29'th May 2024
The speed of growth of a given stock is much higher the smaller it is. Stock size is classified by market capitalization – current share price x number of shares outstanding – with large cap share
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
06:00am, Friday, 24'th May 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of new analyses for BRUKINSA�
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
02:16pm, Monday, 20'th May 2024
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
